Ancrod in acute ischemic stroke: Results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program

Stroke

Volumn 40, Issue 12, 2009, Pages 3796-3803

  Levy, David E ^a,i   Del Zoppo, Gregory J ^b   Demaerschalk, Bart M ^c   Demchuk, Andrew M ^d   Diener, Hans Christoph ^e   Howard, George ^f   Kaste, Markku ^g   Pancioli, Arthur M ^h   Spatareanu, Carmen ^j   Wasiewski, Warren W ^k  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MAYO CLINIC HOSPITAL   (United States)

^d FOOTHILLS HOSPITAL   (Canada)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MÜNSTER   (Germany)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k Infacare   (United States)

more..

Author keywords

Ancrod; Anticoagulant; Cerebral infarction; Defibrinogenation; Fibrinogen; Fibrinolytic agent; Recovery of function; Therapeutics; Treatment outcome

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ANTITHROMBOCYTIC AGENT; FIBRINOGEN; PLACEBO;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLEEDING; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN HERNIA; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATURIA; HUMAN; HYPOKALEMIA; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NAUSEA; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; STROKE; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ACUTE DISEASE; AGED; ANCROD; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; STROKE; TIME FACTORS; TREATMENT FAILURE;

EID: 73449128279     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.565119     Document Type: Article

References (19)

1. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Piñango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssönen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Duci-metiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Després JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-anal-ysis. JAMA. 2005;294:1799-1809.
2. Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR. for the NINDS rtPA Stroke Study Group. Hemostatic activation and outcome after recom-binant tissue plasminogen activator therapy for acute ischemic stroke. Stroke. 2006;37:1798-1804.
3. Dempfle CE, Argiriou S, Kucher K, Müller-Peltzer H, Rübsamen K, Heene DL. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod. Blood. 2000;96:2793-2802.
4. Spellman GG Jr, Macoviak JA, Gralnick HR. Comparison of polymerization of ancrod and thrombin fibrin monomers. Blood. 1977;50: 619-624.
5. Levy DE, del Zoppo GJ. Ancrod: a potential treatment for acute ischemic stroke from snake venom. Toxin Rev. 2006;25:319-329.
6. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE; for the STAT Investigators. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. JAMA. 2000;283:2395-2403.
7. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraeate M, Orgogozo JM; for the ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: A randomised controlled trial. Lancet. 2006;368:1871-1888.
8. Sherman DG, del Zoppo G, Kaste M, Pancioli AM, Demchuk AM, Demaerschalk BM, Albers GW, Wasiewski WW, Levy DE. Effect of average BP and average fibrinogen levels on symptomatic intracranial hemorrhage in studies of ancrod for acute ischemic stroke (abst). Presented at the 6th World Stroke Congress, Vienna; September 25, 2008.
9. del Zoppo GJ, Levy DE, Wasiewski WW, Pancioli AM, Demchuk AM, Trammel J, Demaerschalk BM, Kaste M, Albers GW, Ringelstein EB. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke. 2009;40:1687-1691
10. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke. 1994;25:1755-1759.
11. Levy DE, Trammel J, Wasiewski W. for the Ancrod Stroke Program (ASP) Study Team. Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies. J Stroke Cerebrovasc Dis. 2009;18:23-27.
12. Efron B. Randomizing and balancing a complicated sequential experiment. In: Miller RG, Efron B, Brown BW, Moses L, eds. Biosta-tistics Casebook. New York: Wiley & Sons; 1980.
13. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129.
14. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
15. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;17:1245-1251.
16. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boyson G, Blumki E, Höxter G, Mahegne M-H, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
17. Cytel Corporation, East version 4.0.1.34. Cytel East 4 Manual (electronic). 2005;342-348.
18. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clin Trials. 1984;5:348-361.
19. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.